Healthcare services provider AdaptHealth Corp. (NASDAQ: AHCO) fell short of the market’s revenue expectations in Q2 CY2026, with sales falling 7.5% year on year to $740.3 million. The company’s full-year revenue guidance of $2.87 billion at the midpoint came in 17.6% below analysts’ estimates. Its GAAP loss of $0.98 per share was significantly below analysts’ consensus estimates.
Is now the time to buy AHCO? Find out in our full research report (it’s free for active Edge members).
AdaptHealth (AHCO) Q2 CY2026 Highlights:
- Revenue: $740.3 million vs analyst estimates of $847.2 million (7.5% year-on-year decline, 12.6% miss)
- EPS (GAAP): -$0.98 vs analyst estimates of $0.15 (significant miss)
- Adjusted EBITDA: $132 million vs analyst estimates of $160.3 million (17.8% margin, 17.7% miss)
- The company dropped its revenue guidance for the full year to $2.87 billion at the midpoint from $3.49 billion, a 17.6% decrease
- EBITDA guidance for the full year is $505 million at the midpoint, below analyst estimates of $697.2 million
- Operating Margin: -18.6%, down from 8.2% in the same quarter last year
- Market Capitalization: $893.2 million
StockStory’s Take
AdaptHealth’s second quarter results prompted a significant negative market reaction, as the company reported both revenue and profitability well below Wall Street’s expectations. Management attributed this to a combination of operational inefficiencies in its large West Coast capitated contract and cost pressures from a sudden supplier price increase. CEO Suzanne Foster described the unexpected operational challenges as “not sustainable,” highlighting elevated costs from higher-than-anticipated order volumes and inefficient workflows. Foster also acknowledged that restructuring efforts, including workforce reductions and portfolio simplification, were necessary to address these immediate pressures.
Looking forward, AdaptHealth’s updated guidance reflects caution as the company navigates persistent cost headwinds and ongoing business transformation. Management cited the need for additional time to stabilize the West Coast contract and resolve pricing negotiations with a key manufacturer. Foster emphasized that the company’s future profitability hinges on successfully reengineering its cost structure and capitalizing on its newly focused core business, stating, “These growing pains will make us a stronger, more efficient company.” The company aims to leverage technology and a streamlined portfolio to return to more sustainable margins in the coming year.
Key Insights from Management’s Remarks
Management pointed to a quarter of disruptive change, with core business refocusing and major external cost shocks driving underperformance and a downward revision of full-year expectations.
- West Coast contract inefficiencies: AdaptHealth’s largest capitated contract experienced higher-than-expected order volumes and workflow inefficiencies, especially in urgent orders and sleep resupply products. Management described these pressures as transitory but significant, with Foster noting “operational challenges we did not fully anticipate.”
- Portfolio simplification: The company completed its strategy to streamline operations, announcing the sale of its Diabetes Health business and discontinuing select low-margin Wellness-at-Home products. This was positioned as the end of a multi-year divestiture effort, allowing a tighter focus on sleep, respiratory, and home medical equipment.
- Supplier price shock: AdaptHealth faced an immediate and material price increase from a major manufacturer after a contract termination, resulting in a $30 million second-half headwind. Foster called the event “unusual” and said negotiations are ongoing to mitigate the impact.
- Technology-driven cost reductions: The company is leaning on its myAPP platform and new AI capabilities, such as an AI-powered mask fitting tool, to drive operational efficiency and improve the patient experience. Foster highlighted the rapid adoption of digital tools as a lever to reduce manual labor and support cost-cutting.
- Workforce restructuring: AdaptHealth implemented workforce reductions to deliver $19 million in annualized savings, aiming to maintain delivery standards while lowering overhead in response to shrinking margins and portfolio adjustments.
Drivers of Future Performance
Management’s outlook centers on stabilizing operations, resolving supplier pricing, and driving profitability through a simplified business model and technology adoption.
- Stabilizing West Coast operations: Management expects margin recovery as order volumes normalize and workflow inefficiencies are addressed. The company is working closely with its partner to align practices and streamline logistics, but recognizes that operational improvements will require sustained effort over several quarters.
- Resolving supplier contract terms: The sudden price increase from a major manufacturer remains a key risk. Negotiations are ongoing, and management is exploring alternative suppliers and product mix changes to offset the impact, but acknowledges that near-term margins will be pressured until an agreement is reached.
- Leveraging technology and portfolio focus: AdaptHealth plans to accelerate technology rollouts and reinvest in its core sleep and respiratory businesses. Management believes that a more focused portfolio enables faster deployment of digital tools and AI-powered processes, which should enhance efficiency and support long-term margin improvement.
Catalysts in Upcoming Quarters
In the coming quarters, our analysts will closely watch (1) the pace of operational improvements and cost normalization in the West Coast capitated contract, (2) the outcome of ongoing supplier price negotiations and their effect on gross margins, and (3) execution against the company’s technology-driven efficiency strategy. The resolution of these issues will be critical for AdaptHealth’s ability to deliver on its streamlined business model.
AdaptHealth currently trades at $6.72, down from $10.83 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
Now Could Be The Perfect Time To Invest In These Stocks
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
